Sunovion employees in Fort Lee, N.J. and field teams across the United States are also participating in the community service initiative by engaging in volunteer activities to serve the unique needs of their local communities.
About Sunovion Hands On!
Sunovion is committed to making positive contributions to communities across the country where the Company has an active presence. Through the Sunovion Hands On! community service initiative, employee volunteers are helping to give back to their local communities where they live and work. In its second year, nearly 80 percent of Sunovion’s 1,600 employees nationwide will participate in the program.
Select Nonprofits Served through Sunovion Hands On! in 2013:
Greater-Boston Area
- Boys Girls Club of MetroWest (Marlborough, MA)
- Boys Girls Club of Worcester (Worcester, MA)
- Cradles to Crayons (Brighton, MA)
- Employment Options (Marlborough, MA)
- Fuller Middle School (Framingham, MA)
- Leahy School (Lawrence, MA)
- Learning Center for the Deaf (Framingham, MA)
- Marlborough Public Schools Early Childhood Center (Marlborough, MA)
- Mass Audubon: Broad Meadow Brook (Worcester, MA)
- MSPCA: Animal Care and Adoption Center at Nevins Farm (Methuen, MA)
- New England Center for Homeless Veterans (Boston, MA)
- Room to Grow (Boston, MA)
- Rosie’s Place (Boston, MA)
- The Wish Project (Lowell, MA)
About Sunovion Pharmaceuticals Inc. (Sunovion)
Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion, an indirect, wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd., is headquartered in Marlborough, Mass. More information about Sunovion Pharmaceuticals Inc. is available at www.sunovion.com.
About Dainippon Sumitomo Pharma Co., Ltd. (DSP)
DSP is a top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food and specialty products. DSP aims to produce innovative pharmaceutical products in the Psychiatry Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at www.ds-pharma.com.